New Guidelines Clarify Use of Systemic Therapy in Advanced HCC
ASTRO Issues Clinical Guideline on External Beam Radiation Therapy for Primary Liver Cancers
After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.
FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
COVID-19: What People With Cancer Need to Know (Cancer.net, June 2020)
FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)
U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC
FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib
DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner
Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer
New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients
Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC
Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions
Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial
How Have Hepatocellular Carcinoma Treatments Improved?
Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC
Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC
Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer
Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)
New Study Shows Options for Older Patients With Liver Cancer
Novartis and BeiGene have announced new data from a phase 3 trial that shows tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma
Dr Reddy’s Laboratories announces the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration
JW Therapeutics announces the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma
The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.
Cancer Burden Facing Asian Americans Partly Caused By Racism